News and Events

The administration team and shareholders of Complete Omics are pleased to announce the establishment of a new branch in China, named KangPuBoAo (HangZhou) Biotechnology Inc. (“康普博奥（杭州）生物科技有限公司” in Chinese). This expansion positions Complete Omics as one of the select molecular diagnostic service companies with operations extending beyond national borders.

BALTIMORE, MD – November 28, 2023 --- In a significant move for the biotech industry, Complete Omics Inc., has announced the successful closure of its Series A financing round, with a notable investment from Qiming Venture Partners. This strategic partnership marks a pivotal moment for Complete Omics, enabling the company to accelerate its research and development efforts and expand its innovative diagnostics solutions globally.

Jan 29, 2022 | BALTIMORE – Complete Omics Inc, a multi-omics molecular diagnostics company, today announces the publication of a new peer reviewed paper in Science Advances journal, demonstrating the value of targeting antigens derived from human endogenous retroviruses (HERVs) specifically overexpressed by tumor cells for new immunotherapy approaches

Feb 28, 2022 | BALTIMORE – Complete Omics Inc, a multi-omics molecular diagnostics company, today announces the publication of a new peer reviewed paper in the academic journal CANCERS, presenting a new pipeline developed for validating and absolutely quantifying neoantigens from very limited amount of clinical samples.

Complete Omics has been a pioneer in multi-omics molecular diagnostics since founded and we are humbled and excited to share with you two of the milestones in personalized cancer diagnostics and treatment through our multi-omics platform that we have published on Science Immunology and Science.

NEW YORK – Researchers at Johns Hopkins University have developed a targeted mass spec method for measuring cancer-linked neoantigens. Described in a study published last month in Cancer Immunology Research, the method could prove useful both for studying tumor immunology and in the development of personalized cancer immunotherapies, said Qing Wang, first author on the paper and founder and CEO of clinical omics firm Complete Omics.

NEW YORK (GenomeWeb) – Researchers in the lab of Johns Hopkins University professor Bert Vogelstein have identified a pair of potential peptide biomarkers for ovarian cancer. Described in a study published this week in Proceedings of the National Academy of Sciences, the markers stem from efforts by the lab, which had traditionally focused on cancer genomics, to move more seriously into the proteomic and protein biomarker space, said Qing Wang, a faculty member in Vogelstein’s lab and first author on the study.